SLIT2 and cholangiocarcinoma: Taken together, these results indicated that ROBO1 may serve as a tumor suppressor in CCA progression, and ROBO1E280* is a loss-of-function mutation, interrupting the SLIT2/ROBO1 signaling pathway and reversing the tumor-suppressing effects of wild-type ROBO1.